2003;101:4505–11. 6. Manches O, Frleta D, Bhardwaj N. Dendritic cells in progression and pathology of HIV infection. Trends in Immunology. 2013; 7.
Impact of systemic corticosteroids on the clinical course and outcomes of patients with severe community-acquired pneumonia: a cohort study. J Crit Care. 2011;26(2):193-200. http://www.sciencedirect.com. ezproxy.mcphs.edu/science/article/pii/S0883944110001929. Accessed February 23, 2012.
Hepatology 57: 1333-1342. Shepard, CW, Finelli, L & Alter, MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect 5: 558-567. Vince, B, Hill, JM, Lawitz, EJ, O’Riordan, W, Webster, LR, Gruener, DM, Mofsen, RS, Murillo, A, Donovan, E, Chen, J et al. (2014) A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4.
It provides a discussion on how the false vaccine risks can make it difficult for the scientific community to evaluate actual risks. It mentions that vaccine manufactures are “victims of their own success” (Kwok, 2011) largely due to how safe vaccines have become. It does this by discussing the low risk rates for contracting the disease the vaccine is attempting to prevent and how few cases of contraction of disease cause public outcry. The article also discusses other potential side effects to vaccinations and the frequency of these side effects. It touches on the need for speed in identifying certain side effects so that their correlation to the administration of the vaccine can be ... ... middle of paper ... ...weigh the risks.
Print. 11Rodemann, Joseph F., Erik R. Dubberke, Kimberly A. Reske, Da Hea Seo, and Christian D.Stone. "Incidence of Clostridium Difficile Infection in Inflammatory Bowel Disease. "Clinical Gastroenterology and Hepatology 5.3 (2007): 339-44. Print.
Curr Opin Biotechnol 2012; 23: 900-7. 25. Prabowo SA, Groschel MI, Schmidt ED, et al. Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol 2013; 202(2): 95-104.
Hepatitis C (HCV) virus is the most prevalent blood-blood infection in the United States: with over 4 million persons chronically infected. More than 80% of those infected go on to develop chronic HCV infection leading to many increased risks such as; liver cirrhosis, hepatocellular carcinoma (HCC), liver failure, and related morbidities (O’Brien, 2013). Morbidity and mortality rates remain high due to the fact that 45% to 85% of infected patients remain unaware of their HCV infection because of the asymptomatic nature of this disease process. HCV has a very slow disease progression, which lends to its high mortality rate when diagnosis is found after the liver is already beyond repair (O’Brien, 2013). HCV used to be associated with injecting drug use, however, more times than not the person acquired the virus from a source other than drug use.
Antigenic variation at the infected red cell surface in malaria. Annual Review Of Microbiology, 55673-707. -Lehne, R. (2013). Pharmacology for nursing care. (8th ed., pp.
Chronic Hepatitis C Virus (HCV) infection is a major cause for developing cirrhosis and hepatocellular carcinoma, with an estimated global prevalence of 3% occurring in about 180 million carriers and approximately 4 million people are being newly infected annually (1). According to WHO, HCV is found worldwide with certain countries having chronic infection rates as high as 5% or above. In India 12.5 million people are infected with HCV (2). This virus is spread primarily by blood to blood contact associated with intravenous drug use, poorly sterilized medical equipment and transfusions (3). The gold standard therapy for chronic hepatitis C (CHC) consists of Pegylated Interferon (Peg-IFN) and ribavirin, but reports show that the drugs are not well tolerated (4).
Expert Rev Vaccines 10, 299-306 (2011). 4. Hill, P.C. et al. Longitudinal assessment of an ELISpot test for Mycobacterium tuberculosis infection.